Supporting Patients In Oxford

This pioneering Phase 2 platform trial is evaluating Zanubrutinib therapy in adults with relapsed brain lymphoma. In the first year, 20 patients with this rare and aggressive blood cancer were recruited, with first results due to be presented at an international conference next month. Later this year, recruitment will re-commence for a further 20 patients using a world-first three-drug combination, offering long-term hope for those facing limited treatment options.

Focused on patients with Myelofibrosis, the Fedora trial is tackling a critical area of unmet need, gathering information about whether a combination of treatments is tolerated, and whether it provides a therapeutic benefit to patients. The FEDORA Trial has now completed recruitment, with results expected to be published soon.

One of the TAP Network’s highest recruiting studies, AMMO trial tests a new drug in treating and extending the lives of patients with a rare bone marrow cancer, where treatment options are very limited. The treatment can be taken orally at home, making it much more convenient for patients. The trial has just concluded and results are expected to be published at the end of 2025.

A Phase 2 randomised trial for adults with Richter’s syndrome, a rare and aggressive form of lymphoma. The STELLAR trial is the first randomised trial for Richter’s syndrome in the UK, and it demonstrates the nation’s growing ability to run trials in rare diseases. The study also includes crucial translational research that will help tailor future therapies.